Profile for Novavax Inc. (NVAX)

$ 46.30   1.64 (+3.67%) Volume: 8.08m 4:00 PM EDT 5-Jun-2020
After Hours:  $ 46.50   0.20 (+0.43%) Volume: 72.99k 7:59 PM EDT 5-Jun-2020
Business Description:
Novavax Inc is a clinical-stage vaccine company. It is engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.
Address: 21 Firstfield Road, Gaithersburg, MD, USA, 20878
Telephone: +1 240 268-2000 Website:
Facsimile: N/A Email: [email protected]
CEO: Stanley Charles Erck
Employees: 165 Market Cap: 2.72b
Issue Type: CS
Auditor: Ernst & Young LLP
Last Audit: Unqualified Opinion with Explanation
Indices: N/A
Industry Classifications
Sector: Healthcare CIK: 1000694
Industry: Biotechnology
Sub-Industry:    Biotechnology
NAICS: Biological Product (except Diagnostic) Manufacturing (325414)
SIC: Biological Products, Except Diagnostic Substances (2836)